Ranibizumab (Lucentis) ELISA - High Sensitivity

Ranibizumab (trade name Lucentis, Genentech/Roche) is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is used for the treatment of diseases of the eye in macular degeneration, diabetic retinopathy and retinopathy of prematurity.

The intraocular dose is 1.25 mg to 2.5 mg in 100 ul (0.1ml) injections. The lower dose is usually preferred in premature newborns to prevent retinal blindness. The higher dose(s) is for adults with macular degeneration and severe forms of diabetic retinopathy given indefinitely at 4-6 weeks intervals.

The long-term local and systemic effect of Rabibizumab is unknown because of its long half-life and its suppression of VEGF (vascular endothelium growth factor). Therefore the need for a sensitive and accurate assay is imperative to understand and to prevent potential damaging side effects. Read more about LUCENTIS...

The Ranibizumab (Lucentis) ELISA is a solid phase sandwich enzyme immunoassay. This assays incorporates a microtiter plate shaker in the first two steps of the assay protocol. Sample/calibrators are added to the microtiter plate wells that are coated with protein. Lucentis is a Humanized monoclonal antibody fragment (fab) which binds to the protein coated microtiter plate wells if it is present in the sample . The contents in the wells following an incubation time are washed from the wells and the enzyme conjugate is added. The enzyme conjugate is an anti-Lucentis antibody coupled to the enzyme horseradish peroxidase. Unbound enzyme conjugate is removed after incubation. The wells are washed and a chromogenic substrate is added. The optical density is read on a spectrophotometer at 450nm yielding the concentration of Lucentis which is directly proportional to the optical density. Read more about ELISA...

RESEARCH USE ONLY